Article
Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring.
Nature medicine - 1 Jul 2020
Zviran Asaf, Schulman Rafael C, Shah Minita, Hill Steven T K, Deochand Sunil, Khamnei Cole C, Maloney Dillon, Patel Kristofer, Liao Will, Widman Adam J, Wong Phillip, Callahan Margaret K, Ha Gavin, Reed Sarah, Rotem Denisse, Frederick Dennie, Sharova Tatyana, Miao Benchun, Kim Tommy, Gydush Greg, Rhoades Justin, Huang Kevin Y, Omans Nathaniel D, Bolan Patrick O, Lipsky Andrew H, Ang Chelston, Malbari Murtaza, Spinelli Catherine F, Kazancioglu Selena, Runnels Alexi M, Fennessey Samantha, Stolte Christian, Gaiti Federico, Inghirami Giorgio G, Adalsteinsson Viktor, Houck-Loomis Brian, Ishii Jennifer, Wolchok Jedd D, Boland Genevieve, Robine Nicolas, Altorki Nasser K, Landau Dan A
Abstract excerpt
In many areas of oncology, we lack sensitive tools to track low-burden disease. Although cell-free DNA (cfDNA) shows promise in detecting cancer mutations, we found that the combination of low tumor fraction (TF) and limited number of DNA fragments restricts low-disease-burden monitoring through the prevailing deep targeted sequencing paradigm. We reasoned that breadth may supplant depth of sequencing to overcome...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.